3.27
+0.1(+3.15%)
Currency In USD
| Previous Close | 3.17 |
| Open | 3.12 |
| Day High | 3.31 |
| Day Low | 3.12 |
| 52-Week High | 3.78 |
| 52-Week Low | 0.99 |
| Volume | 1.59M |
| Average Volume | 3.03M |
| Market Cap | 314.79M |
| PE | -1.36 |
| EPS | -2.4 |
| Moving Average 50 Days | 2.65 |
| Moving Average 200 Days | 2.2 |
| Change | 0.1 |
If you invested $1000 in Cabaletta Bio, Inc. (CABA) since IPO date, it would be worth $327 as of March 09, 2026 at a share price of $3.27. Whereas If you bought $1000 worth of Cabaletta Bio, Inc. (CABA) shares 5 years ago, it would be worth $270.47 as of March 09, 2026 at a share price of $3.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with a
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with a
Cabaletta Bio Announces 2026 Strategic Priorities
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to manufacture rese-cel with the automate